13.45
-0.11 (-0.81%)
| Previous Close | 13.56 |
| Open | 13.51 |
| Volume | 344,085 |
| Avg. Volume (3M) | 971,322 |
| Market Cap | 852,175,232 |
| Price / Earnings (TTM) | 9.41 |
| Price / Earnings (Forward) | 8.80 |
| Price / Sales | 2.43 |
| Price / Book | 1.28 |
| 52 Weeks Range | |
| Earnings Date | 28 Apr 2026 |
| Profit Margin | 44.79% |
| Operating Margin (TTM) | 20.06% |
| Diluted EPS (TTM) | 2.23 |
| Quarterly Revenue Growth (YOY) | -3.00% |
| Quarterly Earnings Growth (YOY) | -23.20% |
| Total Debt/Equity (MRQ) | 0.90% |
| Current Ratio (MRQ) | 8.73 |
| Operating Cash Flow (TTM) | 122.59 M |
| Levered Free Cash Flow (TTM) | 73.58 M |
| Return on Assets (TTM) | 8.62% |
| Return on Equity (TTM) | 24.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | InMode Ltd. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.00 |
|
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 15.35% |
| % Held by Institutions | 72.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Doma Perpetual Capital Management Llc | 31 Dec 2025 | 2,838,431 |
| North Growth Management Ltd. | 31 Dec 2025 | 662,000 |
| 52 Weeks Range | ||
| Median | 15.00 (11.52%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 17 Dec 2025 | 15.00 (11.52%) | Hold | 14.31 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | InMode to Participate in the 13th Annual BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference |
| 02 Feb 2026 | Announcement | InMode Responds to Transaction Rumors |
| 28 Jan 2026 | Announcement | Steel Partners Holdings L.P. Announces It Has Presented $18.00 Per Share Offer for 51% of InMode Ltd. to Board of Directors |
| 08 Jan 2026 | Announcement | InMode to Report Fourth Quarter & Full Year 2025 Financial Results and Hold Conference Call on February 10, 2026, Expects Q4 Revenue Between $103.6M-$103.8M |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |